AR114496A1 - Compuestos antiproliferación y usos de los mismos - Google Patents
Compuestos antiproliferación y usos de los mismosInfo
- Publication number
- AR114496A1 AR114496A1 ARP190101062A ARP190101062A AR114496A1 AR 114496 A1 AR114496 A1 AR 114496A1 AR P190101062 A ARP190101062 A AR P190101062A AR P190101062 A ARP190101062 A AR P190101062A AR 114496 A1 AR114496 A1 AR 114496A1
- Authority
- AR
- Argentina
- Prior art keywords
- ring
- nitrogen
- membered
- sulfur
- oxygen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 17
- 229910052757 nitrogen Inorganic materials 0.000 abstract 13
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 11
- 125000005842 heteroatom Chemical group 0.000 abstract 11
- 229910052760 oxygen Inorganic materials 0.000 abstract 11
- 239000001301 oxygen Chemical group 0.000 abstract 11
- 229910052717 sulfur Chemical group 0.000 abstract 11
- 239000011593 sulfur Chemical group 0.000 abstract 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 9
- 229920006395 saturated elastomer Polymers 0.000 abstract 8
- 125000004429 atom Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000001931 aliphatic group Chemical group 0.000 abstract 3
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- -1 -OH Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Abstract
Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, donde: Anillo A es un anillo seleccionado de fenilo, un anillo carbocíclico de 5 - 7 miembros saturado o parcialmente insaturado, un anillo heterocíclico bicíclico de 8 - 12 miembros saturado o parcialmente insaturado que tiene 1 - 2 heteroátomos seleccionados independientemente de nitrógeno, oxígeno, o azufre, un anillo de 5 - 6 miembros de anillo heteroaromático que tiene 1 - 4 heteroátomos seleccionados independientemente de nitrógeno, oxígeno, o azufre; o un anillo heteroaromático bicíclico de 8 - 10 miembros que tiene 1 - 5 heteroátomos seleccionados independientemente de nitrógeno, oxígeno, o azufre; cada R¹ es independientemente hidrógeno o C₁₋₃ alifático opcionalmente sustituido por 1 - 6 halógenos; o dos grupos R¹ se toman opcionalmente en conjunto con sus átomos intervinientes para formar un anillo de 5 - 8 miembros carbocíclico fusionado parcialmente insaturado; cada uno de R² es independientemente hidrógeno, halógeno, -CN, -NO₂, -C(O)OR, -C(O)NR₂, -NR₂, -NRC(O)R, -NRC(O)OR, -NRS(O)₂R, -OR, -P(O)R₂, -SR, -S(O)R, -S(O)₂R, -S(O)(NH)R, -S(O)₂NR₂, o R; o dos grupos R² se toman opcionalmente en conjunto para formar =O; dos grupos R² se toman opcionalmente en conjunto con sus átomos intervinientes para formar un anillo espirocíclico de 3 - 8 miembros saturado que tiene 0 - 2 heteroátomos seleccionados independientemente de nitrógeno, oxígeno o azufre; cada R³ es independientemente hidrógeno, -OH, o C₁₋₃ alifático; o: dos grupos R³ se toman opcionalmente en conjunto para formar =O; o dos grupos R³ se toman opcionalmente en conjunto para formar =CH₂; o dos grupos R³ se toman opcionalmente en conjunto con sus átomos intervinientes para formar un anillo espirocíclico saturado de 5 - 8 miembros que tiene 0 - 2 heteroátomos seleccionados independientemente de nitrógeno, oxígeno o azufre; o dos grupos R³ se toman opcionalmente en conjunto con sus átomos intervinientes para formar un anillo bicíclico de 5 - 8 miembros saturado puenteado que tiene 0 - 2 heteroátomos seleccionados independientemente de nitrógeno, oxígeno o azufre; cada R es independientemente hidrógeno o un grupo opcionalmente sustituido seleccionado de C₁₋₆ alifático, un anillo de 3 - 8 miembros carbocíclico monocíclico saturado o parcialmente insaturado, fenilo, un anillo de 7 - 10 miembros espirobicíclico heterocíclico saturado que tiene 1 - 2 heteroátomos seleccionados independientemente de nitrógeno, oxígeno o azufre, un anillo de 7 - 10 miembros heterocíclico bicíclico fusionado, saturado o parcialmente insaturado que tiene 1 - 2 heteroátomos seleccionados independientemente de nitrógeno, oxígeno, o azufre, un anillo de 4 - 8 miembros heterocíclico monocíclico saturado o parcialmente insaturado que tiene 1 - 2 heteroátomos seleccionados independientemente de nitrógeno, oxígeno, o azufre, o un anillo de 5 - 6 miembros heteroaromático monocíclico que tiene 1 - 4 heteroátomos seleccionados independientemente de nitrógeno, oxígeno, o azufre; o: dos grupos R en el mismo nitrógeno se toman opcionalmente en conjunto con sus átomos intervinientes para formar un anillo de 4 - 7 miembros saturado, parcialmente insaturado, o heteroarilo que tiene 0 - 3 heteroátomos, además del nitrógeno, seleccionados independientemente de nitrógeno, oxígeno y azufre, opcionalmente sustituido con 1 - 2 grupos oxo; ⁻ ⁻ ⁻ ⁻ ⁻ es un enlace simple o un enlace doble; X es -O-, -N(R)-, -N(S(O)₂(R))-, -S-, -S(O)-, -S(O)₂-, -CH₂-, -CH(R³)-, o -C(R³)₂-; m es 0, 1, ó 2; n es 0, 1, 2, 3, 4 ó 5; y p es 0, 1, ó 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661719P | 2018-04-24 | 2018-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114496A1 true AR114496A1 (es) | 2020-09-09 |
Family
ID=66655429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101062A AR114496A1 (es) | 2018-04-24 | 2019-04-23 | Compuestos antiproliferación y usos de los mismos |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10815225B2 (es) |
| EP (2) | EP4043460A1 (es) |
| JP (2) | JP7304892B2 (es) |
| KR (1) | KR20210005151A (es) |
| CN (1) | CN112236428A (es) |
| AR (1) | AR114496A1 (es) |
| AU (1) | AU2019261308B2 (es) |
| BR (1) | BR112020020940A2 (es) |
| CA (1) | CA3098335A1 (es) |
| DK (1) | DK3784666T3 (es) |
| ES (1) | ES2919572T3 (es) |
| HR (1) | HRP20220710T1 (es) |
| HU (1) | HUE058746T2 (es) |
| IL (2) | IL301501A (es) |
| LT (1) | LT3784666T (es) |
| MX (1) | MX2020011089A (es) |
| PL (1) | PL3784666T3 (es) |
| PT (1) | PT3784666T (es) |
| RS (1) | RS63281B1 (es) |
| SG (1) | SG11202009500QA (es) |
| SI (1) | SI3784666T1 (es) |
| TW (1) | TWI813673B (es) |
| WO (1) | WO2019209759A1 (es) |
| ZA (1) | ZA202006071B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019209759A1 (en) | 2018-04-24 | 2019-10-31 | Merck Patent Gmbh | Antiproliferation compounds and uses thereof |
| WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| WO2020236834A1 (en) * | 2019-05-20 | 2020-11-26 | Seshadri Raju | Modified z stents for iliac vein stenting |
| PE20221327A1 (es) | 2019-12-20 | 2022-09-09 | Bayer Ag | Carboxamidas de tiofeno, acidos carboxilicos de tiofeno sustituidos y derivados de estos |
| WO2024073502A1 (en) * | 2022-09-28 | 2024-04-04 | Accutar Biotechnology Inc. | Heterocyclic compounds as e3 ligase inhibitors |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| DE19840028A1 (de) | 1998-09-02 | 2000-03-09 | Max Planck Gesellschaft | Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung |
| DZ3248A1 (fr) | 1999-12-10 | 2001-06-14 | Pfizer Prod Inc | Composés à base de pyrrolo[2,3-d]pyrimidine |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| CN1674929B (zh) | 2002-08-14 | 2013-07-17 | 赛伦斯治疗公司 | 蛋白激酶Nβ的应用 |
| AU2004228668B2 (en) | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
| ZA200509718B (en) | 2003-05-30 | 2007-03-28 | Gemin X Biotechnologies Inc | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| EP2371835A1 (en) | 2003-07-03 | 2011-10-05 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| CN101031569B (zh) | 2004-05-13 | 2011-06-22 | 艾科斯有限公司 | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 |
| EP2161275A1 (en) | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| DK1888550T3 (da) | 2005-05-12 | 2014-09-29 | Abbvie Bahamas Ltd | Apoptosepromotorer |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| KR20140033237A (ko) | 2005-10-07 | 2014-03-17 | 엑셀리시스, 인코포레이티드 | 포스파티딜이노시톨 3-키나아제 억제제 및 이의 사용 방법 |
| CA2628283C (en) | 2005-11-01 | 2017-06-27 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| DK2348023T5 (da) | 2005-12-13 | 2017-05-15 | Incyte Holdings Corp | Heteroaryl-substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus-kinase-inhibitorer |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| NZ572812A (en) | 2006-04-26 | 2010-09-30 | Hoffmann La Roche | THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR |
| SI2526771T1 (sl) | 2006-09-22 | 2017-06-30 | Pharmacyclics Llc | Inhibitorji Bruton tirozin kinaze |
| PT2152701E (pt) | 2007-03-12 | 2016-01-27 | Ym Biosciences Australia Pty | Compostos de fenil amino pirimidina e suas utilizações |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| DK2288610T3 (en) | 2008-03-11 | 2016-11-28 | Incyte Holdings Corp | Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| DE102008031517A1 (de) * | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
| AR076014A1 (es) * | 2009-04-02 | 2011-05-11 | Sanofi Aventis | Derivados de 3- (1,4) oxazepan -4-pirimidona |
| KR20120090092A (ko) | 2009-12-04 | 2012-08-16 | 에프. 호프만-라 로슈 아게 | 모노아민 재흡수 억제제로서의 다이페닐 아제핀 유도체 |
| SG10201510092QA (en) | 2010-12-09 | 2016-01-28 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3256132A1 (en) | 2015-02-13 | 2017-12-20 | Merck Patent GmbH | Pyrimidine derivatives for use in the treatment of cancer |
| WO2019209759A1 (en) | 2018-04-24 | 2019-10-31 | Merck Patent Gmbh | Antiproliferation compounds and uses thereof |
-
2019
- 2019-04-23 WO PCT/US2019/028607 patent/WO2019209759A1/en unknown
- 2019-04-23 HR HRP20220710TT patent/HRP20220710T1/hr unknown
- 2019-04-23 CN CN201980036896.XA patent/CN112236428A/zh active Pending
- 2019-04-23 TW TW108114146A patent/TWI813673B/zh active
- 2019-04-23 PT PT197267925T patent/PT3784666T/pt unknown
- 2019-04-23 EP EP22161962.0A patent/EP4043460A1/en active Pending
- 2019-04-23 EP EP19726792.5A patent/EP3784666B1/en active Active
- 2019-04-23 PL PL19726792.5T patent/PL3784666T3/pl unknown
- 2019-04-23 US US16/391,419 patent/US10815225B2/en active Active
- 2019-04-23 ES ES19726792T patent/ES2919572T3/es active Active
- 2019-04-23 AU AU2019261308A patent/AU2019261308B2/en active Active
- 2019-04-23 LT LTEPPCT/US2019/028607T patent/LT3784666T/lt unknown
- 2019-04-23 JP JP2020559394A patent/JP7304892B2/ja active Active
- 2019-04-23 KR KR1020207033873A patent/KR20210005151A/ko unknown
- 2019-04-23 IL IL301501A patent/IL301501A/en unknown
- 2019-04-23 SI SI201930251T patent/SI3784666T1/sl unknown
- 2019-04-23 AR ARP190101062A patent/AR114496A1/es unknown
- 2019-04-23 RS RS20220537A patent/RS63281B1/sr unknown
- 2019-04-23 DK DK19726792.5T patent/DK3784666T3/da active
- 2019-04-23 CA CA3098335A patent/CA3098335A1/en active Pending
- 2019-04-23 HU HUE19726792A patent/HUE058746T2/hu unknown
- 2019-04-23 MX MX2020011089A patent/MX2020011089A/es unknown
- 2019-04-23 SG SG11202009500QA patent/SG11202009500QA/en unknown
- 2019-04-23 BR BR112020020940-6A patent/BR112020020940A2/pt unknown
- 2019-04-23 IL IL278142A patent/IL278142B2/en unknown
-
2020
- 2020-08-27 US US17/004,109 patent/US11440907B1/en active Active
- 2020-09-30 ZA ZA2020/06071A patent/ZA202006071B/en unknown
-
2022
- 2022-09-07 US US17/930,352 patent/US20230150993A1/en active Pending
-
2023
- 2023-06-05 JP JP2023092450A patent/JP2023101824A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114496A1 (es) | Compuestos antiproliferación y usos de los mismos | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR106798A1 (es) | Inhibidores pirazol de acc y usos de los mismos | |
| AR103138A1 (es) | Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos | |
| AR114236A1 (es) | Inhibidores de la gcn2 y usos de los mismos | |
| AR114235A1 (es) | Inhibidores de gcn2 y usos de los mismos | |
| AR112688A1 (es) | Agonistas del receptor tipo toll 7 (tlr7) que tienen una porción piridina o pirazina, conjugados de estos y métodos y usos de estos | |
| AR114828A1 (es) | Compuestos de pteridinona y sus usos | |
| AR096243A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR106799A1 (es) | Inhibidores éster de acc y usos de los mismos | |
| AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR098721A1 (es) | Inhibidores de biarilo de tirosina quinasa de bruton | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR096242A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR096241A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR094668A1 (es) | Amidas como moduladores de canales de sodio | |
| AR091273A1 (es) | Inhibidores de pirimidinil tirosina quinasa | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR099890A1 (es) | Inhibidores de histona demetilasas | |
| AR092869A1 (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| AR116114A1 (es) | Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak | |
| AR108387A1 (es) | Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor | |
| AR117472A1 (es) | Inhibidores de tienopiridina de ripk2 |